U.S. Markets open in 9 hrs 27 mins
  • S&P Futures

    4,159.25
    -5.50 (-0.13%)
     
  • Dow Futures

    33,982.00
    -34.00 (-0.10%)
     
  • Nasdaq Futures

    13,905.00
    -14.25 (-0.10%)
     
  • Russell 2000 Futures

    2,229.10
    -9.30 (-0.42%)
     
  • Crude Oil

    61.08
    -0.27 (-0.44%)
     
  • Gold

    1,793.90
    +0.80 (+0.04%)
     
  • Silver

    26.58
    +0.01 (+0.06%)
     
  • EUR/USD

    1.2039
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    1.5640
    +0.0020 (+0.13%)
     
  • Vix

    17.50
    -1.18 (-6.32%)
     
  • GBP/USD

    1.3938
    +0.0006 (+0.0418%)
     
  • USD/JPY

    107.9990
    -0.0440 (-0.0407%)
     
  • BTC-USD

    53,823.84
    -2,259.22 (-4.03%)
     
  • CMC Crypto 200

    1,236.38
    -26.58 (-2.10%)
     
  • FTSE 100

    6,895.29
    +35.42 (+0.52%)
     
  • Nikkei 225

    29,058.73
    +550.18 (+1.93%)
     

Novavax Partners With Poland's Mabion For COVID-19 Vaccine Production: Bloomberg

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Poland-based biotech firm Mabion has signed a preliminary agreement to manufacture Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, reports Bloomberg.

  • The polish company will get 40 million zlotys ($11 million) in loans and equity from a state-run fund to support doubling its production capacity in Poland.

  • Mabion will start commercial-scale production trials of Novavax shot.

  • European Union countries such as Poland have struggled to secure supplies of COVID-19 vaccines sourced by Brussels, leading some to step up their efforts.

  • It has also secured eight million doses of Novavax's vaccine as part of EU joint purchases. The vaccine is yet to be approved by EU regulators.

  • Mabion said it expects the technology transfer and verification to be complete by the middle of 2021.

  • The country had to slow the pace of its vaccinations earlier this year due to supply shortfalls. Faced with a renewed surge in virus cases, Poland is now considering buying doses from China.

  • Price Action: NVAX shares are down 3.6% at $198.6 in market trading hours on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.